Pharsight

Copiktra is owned by Secura.

Copiktra contains Duvelisib.

Copiktra has a total of 5 drug patents out of which 0 drug patents have expired.

Copiktra was authorised for market use on 24 September, 2018.

Copiktra is available in capsule;oral dosage forms.

Copiktra can be used as for the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll).

Drug patent challenges can be filed against Copiktra from September, 2022.

The generics of Copiktra are possible to be released after 17 May, 2032.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182	SECURA	Substituted isoquinolin-1(2H)-ones, and methods of use thereof	Feb, 2030 (7 years from now)
USRE46621	SECURA	Processes for preparing isoquinolinones and solid forms of isoquinolinones	May, 2032 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216982	SECURA	Certain chemical entities, compositions and methods	Jan, 2029 (5 years from now)
US9840505	SECURA	Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof	Jan, 2032 (8 years from now)
US11312718	SECURA	Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one	Jan, 2032 (8 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 24, 2023
Orphan Drug Exclusivity (ODE)	Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL